Pfizer Inc

NYSE: PFE
$25.75
-$0.02 (-0.1%)
Real Time Data Delayed 15 Min.

PFE Articles

24/7 Wall St. screened the Merrill Lynch Income Portfolio portfolio looking for high-yielding Buy-rated companies and found the following five from different sectors that are solid plays now.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Apple, Intel and Pfizer above all other Dow stocks.
It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the report.
24/7 Wall St. has put together a preview of Apple, Pfizer and other Dow companies scheduled to report their quarterly results this week.
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Here is a slate of 15 companies that most retirees likely would want to own in their portfolio now, including AT&T, Boeing, Pfizer and Walmart.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks. Many others saw sizable increases in their short interest.